If approved, paliperidone palmitate 3-monthly injection will be the first once-every-three-months treatment for schizophrenia in the UK Janssen UK announced today that the Committee for Medicinal ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Long-acting injectable formulations of paliperidone, ...

Paliperidone 3 mg, 6 mg, 9 mg; extended-release tabs. Paliperidone is the major active metabolite of risperidone. Although the mechanism of action of this atypical antipsychotic is unknown, the ...

This analysis used propensity score matching of subjects from randomized placebo-controlled schizophrenia studies to compare paliperidone ER 6–12 mg/day with risperidone 2–4 mg/day and risperidone 4–6 ...

The FDA approved a new monthly paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia in adults, Luye Pharma announced. An atypical antipsychotic, ...

Paliperidone (as palmitate) 1092mg/3.5mL, 1560mg/5mL; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp) for at ...

Of 855 subjects screened, 652 (76%) were randomized to either paliperidone palmitate (n = 488) or placebo (n = 164); 476 and 160, respectively, were in the ITT analysis set (Figure 1). All ITT ...

TITUSVILLE, N.J., March 29, 2015 /PRNewswire/ -- Three-month paliperidone palmitate, an investigational atypical antipsychotic, significantly delayed time to relapse compared to placebo in patients ...

Please provide your email address to receive an email when new articles are posted on . Paliperidone palmitate appeared to benefit Black patients with recent-onset schizophrenia or schizophreniform ...